Key Highlights
• Continued growth of digital health and patient monitoring technologies
• Active clinical development in regenerative and aesthetic medical devices
• Increasing importance of accuracy validation studies
• Greater use of comparative clinical trials for product differentiation
• Strong emphasis on generating real-world clinical evidence
The May 2026 MFDS medical device approvals provide valuable insight into the evolving priorities of Korea’s medical device industry. Although only two devices received approval during the month, both reflect key trends shaping future medical device development.
One approved study involved the HiCardi M350 patient monitoring device, which is being evaluated through a confirmatory clinical trial comparing its blood pressure measurement accuracy against a conventional auscultatory blood pressure monitor. This highlights the growing importance of digital health technologies and the need for reliable physiological monitoring data in clinical practice.
The second approved study involved a tissue repair biomaterial designed to improve crow’s feet wrinkles. The clinical trial compares the product’s safety and effectiveness against Rejuran®, reflecting continued innovation and investment within Korea’s regenerative medicine and aesthetic medical device sectors.
Notably, both approvals utilize clinical study designs focused on demonstrating measurable clinical performance rather than simple technical functionality. This indicates that evidence-based regulatory strategies are becoming increasingly important, while comparative clinical studies are emerging as a key approach for establishing product differentiation and market value.
Overall, the May 2026 approval data suggests that digital monitoring technologies and regenerative aesthetic devices remain important growth areas within the Korean medical device market. Clinical validation, real-world performance, and demonstrable patient benefits are expected to remain critical success factors for future device development and regulatory approval.